BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 2870354)

  • 1. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia.
    O'Donovan R; Baldwin D; Hammer M; Moniz C; Parsons V
    Lancet; 1986 Apr; 1(8486):880-2. PubMed ID: 2870354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercalcaemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations.
    Hutchison AJ; Were AJ; Boulton HF; Mawer EB; Laing I; Gokal R
    Nephron; 1996; 72(1):52-8. PubMed ID: 8903861
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients.
    Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP
    Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose calcium carbonate with stepwise reduction in dialysate calcium concentration: effective phosphate control and aluminium avoidance in haemodialysis patients.
    Sawyer N; Noonan K; Altmann P; Marsh F; Cunningham J
    Nephrol Dial Transplant; 1989; 4(2):105-9. PubMed ID: 2496350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis.
    Morinière P; Fournier A; Leflon A; Hervé M; Sebert JL; Grégoire I; Bataille P; Guéris J
    Nephron; 1985; 39(4):309-15. PubMed ID: 3982576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
    Ittel TH; Schäfer C; Schmitt H; Gladziwa U; Sieberth HG
    Klin Wochenschr; 1991 Jan; 69(2):59-67. PubMed ID: 2027271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia.
    Wheeler DC; Smith B; Walls J
    Lancet; 1986 Jun; 1(8494):1380. PubMed ID: 2872489
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2.
    Mornière P; Maurouard C; Boudailliez B; Westeel PF; Achard JM; Boitte F; el Esper N; Compagnon M; Maurel G; Bouillon R
    Nephron; 1992; 60(2):154-63. PubMed ID: 1552999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of zero magnesium dialysate and magnesium supplements on ionised calcium concentration in patients on regular dialysis treatment.
    Breuer J; Moniz C; Baldwin D; Parsons V
    Nephrol Dial Transplant; 1987; 2(5):347-50. PubMed ID: 3122112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-calcium dialysis fluid and oral calcium carbonate in CAPD. A method of controlling hyperphosphataemia whilst minimizing aluminium exposure and hypercalcaemia.
    Hutchison AJ; Freemont AJ; Boulton HF; Gokal R
    Nephrol Dial Transplant; 1992; 7(12):1219-25. PubMed ID: 1337163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma aluminium levels in patients on maintenance haemodialysis fall when oral aluminium hydroxide is withdrawn.
    Wallace MR; Pybus J
    N Z Med J; 1983 Oct; 96(742):793-5. PubMed ID: 6578451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Effects on acidosis, on parathyroid function, and on calcemia.
    Anelli A; Brancaccio D; Damasso R; Padovese P; Gallieni M; Garella S
    Nephron; 1989; 52(2):125-32. PubMed ID: 2500612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients.
    Jespersen B; Jensen JD; Nielsen HK; Lauridsen IN; Andersen MJ; Poulsen JH; Gammelgaard B; Pedersen EB
    Nephrol Dial Transplant; 1991; 6(2):98-104. PubMed ID: 1857534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity?
    Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ
    Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful control of hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis using magnesium carbonate and calcium carbonate as phosphate binders.
    Parsons V; Baldwin D; Moniz C; Marsden J; Ball E; Rifkin I
    Nephron; 1993; 63(4):379-83. PubMed ID: 8459870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Replacement of aluminum-containing phosphate binders by calcium and magnesium carbonates in long-term hemodialysis].
    Zellweger U; Zaugg PY; Dambacher M; Binswanger U; Gautschi K; Hany A
    Dtsch Med Wochenschr; 1989 Apr; 114(17):659-64. PubMed ID: 2707134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of calcium carbonate to treat the hyperphosphataemia of chronic renal failure.
    Williams B; Vennegoor M; O'Nunan T; Walls J
    Nephrol Dial Transplant; 1989; 4(8):725-9. PubMed ID: 2510082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
    Bro S; Brandi L; Olgaard K
    Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation.
    Morinière P; Vinatier I; Westeel PF; Cohemsolal M; Belbrik S; Abdulmassih Z; Hocine C; Marie A; Leflon P; Roche D
    Nephrol Dial Transplant; 1988; 3(5):651-6. PubMed ID: 3146723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.